Menu
← Oncology Approval Tracker
FDA DECISION ·
Alunbrig
brigatinib · ARIAD Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic ALK-positive non-small cell lung cancer identified by an FDA-approved test, with the prior crizotinib treatment restriction removed.
LAMPGEN ANALYSIS
Why it matters
Converted the accelerated indication to regular approval and allowed treatment without prior crizotinib.
What research teams should watch
Confirm ALK status and build in early respiratory monitoring and dose escalation checks.
PRIMARY RECORDS